Vaxcyte
PCVX
336 hedge funds and large institutions have $9.44B invested in Vaxcyte in 2026 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 129 increasing their positions, 81 reducing their positions, and 25 closing their positions.
184% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 25
69% more funds holding in top 10
Funds holding in top 10: 13 → 22 (+9)
59% more repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 81
39% more capital invested
Capital invested by funds: $6.81B → $9.44B (+$2.63B)
14% more funds holding
Funds holding: 295 → 336 (+41)
0.2% more ownership
Funds ownership: 112.72% → 112.93% (+0.2%)
37% less call options, than puts
Call options by funds: $64.8M | Put options by funds: $103M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$173M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$144M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$68.2M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$64.6M |
| 5 |
Jennison Associates
New York
|
+$55.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$74.6M |
| 2 |
D.E. Shaw & Co
New York
|
-$41.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$29.3M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$20.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$19.1M |
PCVX Hedge Fund Activity: Q1 2026 in Review
336 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2026, worth a combined $9.44B — up 39% from $6.81B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new PCVX positions and 25 closed out — a net gain of 46 holders — while 129 added to existing stakes and 81 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $173M. The largest seller was Adage Capital Partners, cutting an estimated $74.6M.
- 336 institutional investors held Vaxcyte (PCVX) as of Q1 2026, up from 295 in Q4 2025.
- Funds reported $9.44B of Vaxcyte stock for Q1 2026, up 39% quarter-over-quarter.
- 71 funds opened new Vaxcyte positions in Q1 2026 and 25 closed out, a net change of +46 holders.
- The largest Vaxcyte buyer in Q1 2026 was Janus Henderson Group, an estimated $173M added.
- The largest Vaxcyte seller in Q1 2026 was Adage Capital Partners, an estimated $74.6M sold.
Based on aggregated 13F filings for Q1 2026.